Pharmaceutical & Life Sciences
River Birch partners with pharmaceutical, biotech, and healthcare services companies at critical inflection points — providing the capital, expertise, and relationships that convert scientific potential into enterprise value.
Request a ConsultationWhat We Do
01
Minority and majority investments in commercial-stage pharmaceutical and life sciences businesses. We partner with management teams navigating rapid scale with operational rigor.
Learn More02
Board-level counsel on M&A strategy, commercial launch readiness, portfolio optimization, and regulatory positioning. We act as long-term partners, not transactional advisors.
Learn More03
Embedded operational support through our network of senior pharma executives. From commercial excellence to supply chain resilience, we help companies execute with precision.
Learn MoreOur Approach
We do not pursue diversification for its own sake. River Birch concentrates expertise in therapeutic areas where we possess genuine scientific and commercial insight — enabling us to underwrite risk that generalist capital cannot.
Discuss a MandateWe access transactions through scientific advisory networks, KOL relationships, and decade-long relationships with investment banks specializing in life sciences.
Clinical, regulatory, commercial, and financial diligence conducted by a team with direct industry operating experience — not just analytical expertise.
Board representation, executive-in-residence programs, and curated introductions to our commercial and regulatory network throughout the hold period.
We pursue strategic exits to large-cap pharma acquirers or public markets — timed to maximize enterprise value, not driven by fund mechanics.
Perspectives
Market Analysis
Patent cliffs, biosimilar pressure, and pipeline attrition are forcing large-cap pharma to pursue inorganic growth at unprecedented velocity. We examine the opportunity set for well-positioned specialty assets.
Regulatory
The implications for late-stage asset valuations and portfolio strategy.
Sector Insight
A framework for evaluating patient population economics and pricing durability.
Leadership
Former EVP of Corporate Development at a top-10 global pharmaceutical company. Led transactions exceeding $12B in aggregate value across oncology and rare disease.
MD/MBA. Practiced internal medicine before transitioning to McKinsey's Healthcare Practice, then private equity. Deep expertise in clinical operations and market access strategy.
Previously with Blackstone Life Sciences and Goldman Sachs Healthcare IBD. Focuses on deal structuring and relationship management with large-cap strategic acquirers.
Former CFO of a publicly traded specialty pharma company. Oversees portfolio operations, fund administration, and investor relations for River Birch's LP base.